** Shares of Innovent Biologics 1801.HK climb 3.2% to HK$36.65, on track for the biggest one-day pct rise since Dec. 9
** Innovent Biologics says China's National Medical Products Administration (NMPA) has approved second New Drug Application (NDA) of DOVBLERON, which is an oral ROS1 inhibitor for treatment of adult patients with metastatic ROS1-positive non-small cell lung cancer
** Says the NDA was accepted by the U.S. Food and Drug Administration for priority review in December 2024
** Hang Seng Commerce & Industry Index .HSNC and healthcare index .HSCIH both gain 0.4% while Hang Seng Index .HSI adds 0.2%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。